...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Reports of Exempt Distribution

"It is generally thought that the OTC market values a company more than it should be due to the unknown unknowns,"

narmac I believe the opposite is true. Value is reflected in the share price. The fact that the OTC restricts liquidity ( which affects share price) does not bode well for Zenith shareholders as things stand. This makes the only salvation for shareholders in a meaningful way is the sale of it and that's unfortunate.

 

Koo

Share
New Message
Please login to post a reply